from pharmadata import cdiscpilotsdtm
meta = cdiscpilotsdtm.meta('ti')
print(f"Rows: {meta.number_rows:,} Columns: {meta.number_columns}")Rows: 31 Columns: 5ti
ti
Trial Inclusion/ Exclusion Criteria
Structure: One record per I/E criterion
Variables
Show variable specs
shape: (5, 5)
| variable | label | type | mandatory | role |
|---|---|---|---|---|
| str | str | str | str | str |
| "STUDYID" | "Study Identifier" | "String" | "Yes" | "IDENTIFIER" |
| "DOMAIN" | "Domain Abbreviation" | "String" | "Yes" | "IDENTIFIER" |
| "IETESTCD" | "Inclusion/Exclusion Criterion Short Name" | "String" | "Yes" | "TOPIC" |
| "IETEST" | "Inclusion/Exclusion Criterion" | "String" | "Yes" | "SYNONYM QUALIFIER" |
| "IECAT" | "Inclusion/Exclusion Category" | "String" | "Yes" | "GROUPING QUALIFIER" |
Examples
from great_docs import tbl_explorer
from pharmadata import cdiscpilotsdtm
tbl_explorer(cdiscpilotsdtm.ti.head(10))PolarsRows10Columns5 | |||||
STUDYID str |
DOMAIN str |
IETESTCD str |
IETEST str |
IECAT str |
|
|---|---|---|---|---|---|
| 0 | CDISCPILOT01 | TI | INCL01 | Males and postmenopausal females at least 50 years of age. | INCLUSION |
| 1 | CDISCPILOT01 | TI | INCL02 | Diagnosis of probable AD as defined by NINCDS and the ADRDA guidelines (Protocol Attachment LZZT.7). | INCLUSION |
| 2 | CDISCPILOT01 | TI | INCL03 | MMSE score of 10 to 23. | INCLUSION |
| 3 | CDISCPILOT01 | TI | INCL04 | Modified Hachinski Ischemic Scale score of <= 4. (Protocol Attachment LZZT.8). | INCLUSION |
| 4 | CDISCPILOT01 | TI | INCL05 | CNS imaging (CT scan or MRI of brain) compatible with AD within past 1 year. | INCLUSION |
| 5 | CDISCPILOT01 | TI | INCL06 | Investigator has obtained informed consent signed by the patient (and/or legal representative) and by the caregiver. | INCLUSION |
| 6 | CDISCPILOT01 | TI | INCL07 | Geographic proximity to investigator's site that allows adequate follow-up. | INCLUSION |
| 7 | CDISCPILOT01 | TI | INCL08 | Caregiverwill monitor administration of prescribed medications, and will be responsible for the overall care of the patient at home. | INCLUSION |
| 8 | CDISCPILOT01 | TI | EXCL09 | Persons who have previously completed or withdrawn from this study or any other investigating xanomeline TTS or the oral formulation of xanomeline. | EXCLUSION |
| 9 | CDISCPILOT01 | TI | EXCL10 | Use of any investigational agent or approved Alzheimer's therapeutic medication within 30 days prior to enrollment into the study. | EXCLUSION |